Form 4: Twist Bioscience Exec Sells Shares for Tax Obligations

Twist Bioscience Senior VP Dennis Cho sold 94 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, reported a transaction on September 15, 2025.
• The transaction involved the disposition of 94 shares of common stock at a price of $25.328 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
• The sale was not a discretionary trade by Mr. Cho.
• Following this transaction, Mr. Cho beneficially owns 102,943 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes, indicating a neutral sentiment as it does not reflect a change in the insider's view of the company's prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This 'sell to cover' transaction is a common and standard practice for executives in publicly traded companies when Restricted Stock Units (RSUs) vest, as it addresses the tax liabilities associated with the equity compensation without requiring a personal cash outlay from the executive.

Comparison to Industry Standards

• The 'sell to cover' mechanism for satisfying tax withholding obligations on vested equity awards is a widely adopted practice across various industries and is considered a standard component of executive compensation plans.
• This transaction aligns with typical corporate governance practices for managing equity compensation and tax compliance, similar to what is observed at comparable biotechnology or technology companies that grant RSUs to their executives.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by an executive to satisfy tax obligations related to vested equity. Such non-discretionary sales do not typically reflect a change in the executive's outlook on the company's performance or prospects. Therefore, the filing provides no new fundamental information that would warrant a change in an investment thesis, leading to a 'hold' recommendation.

Keywords

Twist Bioscience, TWST, Form 4, Insider Transaction, Stock Sale, RSU, Tax Withholding, Equity Compensation